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OBJECTIVE—The precise molecular mechanisms contributing
to the development of insulin resistance, impaired glucose toler-
ance (IGT), and type 2 diabetes are largely unknown. Altered
endogenous glucocorticoid metabolism, including 11-hydroxy-
steroid dehydrogenase type 1 (11-HSD1), which generates ac-
tive cortisol from cortisone, and 5-reductase (5R), which
inactivates cortisol, has been implicated.
RESEARCH DESIGN AND METHODS—A total of 101 obese
patients (mean age 48  7 years, BMI 34.4  4.3 kg/m2, 66
women, 35 men) underwent 75-g oral glucose tolerance testing
(OGTT), body composition analysis (dual-energy X-ray absorpti-
ometry), assessment of glucocorticoid metabolism (24-h urine
steroid metabolite analysis by gas chromatography/mass spec-
trometry), and subcutaneous abdominal adipose tissue biopsies.
RESULTS—A total of 22.7% of women had IGT compared with
34.2% of men. Two women and five men were diagnosed with
type 2 diabetes. In women, adipose 11-HSD1 expression was
increased in patients with IGT and correlated with glucose levels
across the OGTT (R  0.44, P  0.001) but was independent of
fat mass. Total glucocorticoid secretion was higher in men with
and without IGT (normal 13,743  863 vs. 7,453  469 g/24 h,
P  0.001; IGT 16,871  2,113 vs. 10,133  1,488 g/24 h, P 
0.05), and in women, it was higher in those with IGT (7,453 469
vs. 10,133 1,488 g/24 h, P 0.001). In both sexes, 5R activity
correlated with fasting insulin (men R  0.53, P  0.003; women
R  0.33, P  0.02), insulin secretion across an OGTT (men R 
0.46, P  0.01; women R  0.40, P  0.004), and homeostasis
model assessment of insulin resistance (men R 0.52, P 0.004;
women R  0.33, P  0.02).
CONCLUSIONS—Increased adipose 11-HSD1 expression in
women may contribute to glucose intolerance. Enhanced 5R
activity in both sexes is associated with insulin resistance but not
body composition. Augmented glucocorticoid inactivation may
serve as a compensatory, protective mechanism to preserve
insulin sensitivity. Diabetes 57:2652–2660, 2008
Despite the severe health consequences of obe-sity (1) and the alarming rate at which itsprevalence is increasing (2), many questionsremain unanswered with regard to its pathogen-
esis and etiology. Insulin resistance and obesity are tightly
associated, yet the molecular mechanisms that underpin
this relationship are unknown. Insulin resistance has been
implicated as central not only to the development of
obesity itself but also its complications, including dyslipi-
demia, thromboembolic disease, and hypertension (3).
Furthermore, it is a feature of many other clinical condi-
tions, including polycystic ovary syndrome (PCOS), where
the degree of insulin resistance exceeds that observed in
body composition–matched control subjects (4). The as-
sociation between insulin resistance and obesity almost
certainly explains the dramatic relationship between obe-
sity and type 2 diabetes (5,6). Type 2 diabetes evolves from
a state of insulin resistance with hyperinsulinema neces-
sary to maintain glucose tolerance. Type 2 diabetes is
manifest when insulin secretion fails to meet demands,
with consequent hyperglycemia and eventual pancreatic
-cell failure. Impaired glucose tolerance (IGT), defined as
a 2-h glucose concentration7.8 mmol/l but11.1 mmol/l
after 75-g oral glucose testing (OGTT), significantly in-
creases the risk of progression to type 2 diabetes (7), and
although rates of progression to type 2 diabetes are
variable, they may exceed 10% per year (8,9). Although the
benefits of lifestyle intervention are clear (9), the molecu-
lar mechanisms that cause IGT and, similarly, the mecha-
nisms by which IGT progresses to type 2 diabetes are
largely unknown.
The role of endogenous glucocorticoids in the develop-
ment of obesity and insulin resistance has been widely
speculated on based upon observation in patients with
glucocorticoid excess (Cushing’s syndrome). These pa-
tients develop a classical phenotype including central
obesity, insulin resistance, and in some cases type 2
diabetes. However, simple obesity and insulin resistance
are not caused by subclinical endogenous glucocorticoid
excess; circulating cortisol levels in obese patients are not
elevated (10). Tissue-specific glucocorticoid metabolism,
however, may be important. The enzyme 11-hydroxy-
steroid dehydrogenase type 1 (11-HSD1) is highly ex-
pressed in liver, adipose tissue, and muscle and generates
the active glucocorticoid cortisol from inactive cortisone
and therefore amplifies local glucocorticoid action (11).
However, 11-HSD1 is a bidirectional enzyme and is
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capable of inactivating cortisol to cortisone. Critically, the
directionality of 11-HSD1 activity is cofactor (NADPH)
dependent, which is supplied by a tightly associated
endolumenal enzyme, hexose-6-phopshate dehydrogenase
(H6PDH). Decreases in H6PDH expression and activity
decrease oxoreductase and increase dehydrogenase activ-
ity (12,13). Recently, much attention has focused on
pharmacological manipulation of cortisol metabolism as a
therapeutic strategy. Selective 11-HSD1 inhibitors admin-
istered to rodents and primates decrease local glucocorti-
coid generation, improve glucose tolerance, increase
insulin sensitivity, and may promote weight loss (14–17).
In contrast to the action of 11-HSD1, the A-ring reducta-
ses (5-reductase type 1 [5R1] and type 2 [5R2] and
5-reductase) inactivate cortisol, decreasing local glu-
cocorticoid availability to bind and activate the glucocor-
ticoid receptor (GR). 5R1 is expressed in skin and
adipose tissue (18,19) and 5R2 in prostate, epididymis,
and seminal vesicles; both isozymes are expressed in the
liver (18).
Studies published to date have focused principally on
the role of cortisol metabolism in the pathogenesis of
obesity rather than that of insulin resistance. We have
performed a detailed clinical study in a large cohort of
obese patients exploring the concept that cortisol metab-
olism is an important regulator of insulin sensitivity and
that this may be independent of fat mass. We have
hypothesized that decreased local glucocorticoid availabil-
ity (through decreased 11-HSD1 and/or increased A-ring
reductase activity) will represent a novel physiological
adaptive response to preserve insulin sensitivity in a
cohort of patients predisposed to the development of
insulin resistance, IGT, and type 2 diabetes.
RESEARCH DESIGN AND METHODS
The study was approved by the South Birmingham Local Research Ethics
Committee, and all subjects gave informed, written consent. A total of 101
obese volunteers (35 male, 66 female, mean age  SD 48  7 years, mean BMI
34.4 4.3 kg/m2) were recruited following local advertisement and underwent
the clinical protocol described below. Patients had no significant past medical
history, and none had received glucocorticoid therapy (oral, topical, or
inhaled) within the last 12 months. All patients had normal blood counts and
renal function.
Subjects were investigated in the fasting state. Blood samples were drawn
at 9 A.M. for measurement of total cholesterol, triglycerides, cortisol, corti-
sone, glucose, insulin, and A1C. Measurements of BMI, waist circumference
(measured supine, at the level of the umbilicus), hip circumference (at the
level of the greater trochanter), and blood pressure (average of three readings,
measured supine after 10 min rest using Dynamap [Critikon, Tampa, FL]) were
also taken. Patients underwent a standard 75-g oral glucose tolerance test,
with samples taken at 30-min intervals for 120 min for measurement of insulin
and glucose.
In the fasting state, all patients had an abdominal subcutaneous adipose
tissue biopsy (10–15 cm lateral to the umbilicus) performed under local
anesthetic (1–2 ml of 1% lidocaine) in order to obtain250–500 mg of adipose
tissue. The sample was immediately placed in RNALater (Ambion, Austin, TX)
and, after initial storage for 24 h at room temperature, was stored at	20°C for
subsequent total RNA extraction, reverse transcription, and real-time PCR
analysis.
In addition, all patients performed a 24-h urine collection for corticosteroid
metabolite analysis (20). Body composition analysis was performed using
dual-energy X-ray absorptiometry (DEXA) with a total body scanner (QDR
45OO; Hologic, Bedford, MA). Coefficients of variation (CVs) for multiple
TABLE 1
Clinical and serum biochemical characteristics of obese men and women with normal or IGT
Women Men
Normal IGT P Normal IGT P
n 48 15 17 12
Age (years) 48 7 46 8 0.39 48 8 53 8 0.11
Systolic blood pressure (mmHg) 124 17 127 12 0.52 135 16* 139 22 0.60
Diastolic blood pressure (mmHg) 72 11 76 12 0.28 80 14* 79 10 0.88
Anthropometry
BMI (kg/m2) 34.3 4.4 36.4 3.8 0.09 33.4 5.1 34.7 3.9 0.47
Waist circumference (cm) 103 9.0 111 9 0.002 114 13 116 10 0.57
WHR 0.87 0.05 0.90 0.05 0.05 0.98 0.07† 0.99 0.04† 0.46
Serum biochemistry
Fasting glucose (mmol/l) 4.6 0.6 5.0 0.4 0.02 4.8 0.5 5.4 0.6* 0.009
2-h glucose (mmol/l) 6.0 1.0 8.8 0.9 0.001 5.4 1.4* 9.2 1.5 0.001
Fasting insulin (IU/l) 10.0 7.2 12.3 6.3 0.27 8.7 3.9 12.1 7.2 0.12
2-h insulin (IU/l) 97.8 66.0 128 58.0 0.12 52.0 40.9* 97.6 56.7 0.02
AUC insulin (IU  l	1  h	1) 167.6 91.8 173.7 67.6 0.81 162.6 75.5 158.9 107.6 0.92
A1C (%) 5.4 0.5 5.7 0.4 0.08 5.3 0.3 5.9 0.9 0.03
HOMA-%B 141.6 52.2 143.5 52.6 0.90 119.2 32.6 118.9 44.9 0.98
HOMA-%S 104.6 71.5 78.2 61.8 0.20 101.5 60.1 75.7 42.1 0.20
HOMA-R 1.5 1.0 1.8 0.9 0.25 1.3 0.6 1.3 1.1 0.10
Total cholesterol (mmol/l) 5.0 1.0 5.3 1.0 0.29 5.3 0.9 5.0 0.7 0.48
Triglycerides (mmol/l) 1.3 0.6 1.6 0.6 0.11 2.0 1.8* 1.7 0.8 0.57
Cortisol (nmol/l) 216 103 204 102 0.70 320 163‡ 239 80 0.12
Cortisone (nmol/l) 64 26 55 22 0.30 66 20 73 19* 0.42
Body composition (DEXA)
Trunk fat mass (kg) 19.5 5.0 21.7 4.3 0.14 16.8 4.7 19.2 4.8 0.22
Trunk fat-free mass (kg) 25.2 3.2 26.1 4.3 0.39 34.6 4.4† 35.7 3.9† 0.50
Total fat mass (kg) 38.8 9.2 41.7 9.3 0.30 29.9 7.7† 34.4 8.9‡ 0.17
Total fat-free mass (kg) 48.6 5.7 50.2 8.4 0.39 66.9 8.1† 68.7 7.3† 0.54
Total % fat 43.0 4.3 44.1 5.0 0.41 29.7 4.2† 32.2 5.6† 0.21
Trunk fat–to–limb fat ratio 1.1 0.2 1.2 0.3 0.09 1.4 0.14† 1.4 0.23 0.71
Data are means  SD unless otherwise indicated. *P  0.05; †P  0.0001; ‡P  0.01 vs. women.
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scans were3%. Regional fat mass (trunk and leg) was analyzed as previously
described (21).
Biochemical assays. Blood counts, urea, creatinine and electrolytes, choles-
terol, triglycerides, liver chemistry, glucose, and A1C were measured using
standard laboratory methods (Roche Modular system; Roche, Lewes, U.K.).
Insulin was measured using a commercially available colorimetric ELISA
(Mercodia, Uppsala, Sweden) with an in-house CV of 5%. Cortisol was
measured using a coat-a-count radioimmunoassay (Diagnostic Products, Los
Angeles, CA) as per the manufacturer’s guidelines. Cortisone was assayed
after extraction from serum followed by radioimmunoassay of the extract
with 125I-cortisone and Sac-Cel (IDS, Tyne and Weir, U.K.) second antibody
separation (22). The CV for 10 consecutive assays was 15% for values
between 50 and 100 nmol/l and 10% for values over 100 nmol/l.
Calculated measures of pancreatic -cell function and insulin resistance
were made using the homeostasis model assessment (HOMA) 2 model (23).
The HOMA of -cell function (HOMA %B) values provide an index of
pancreatic islet -cell function relative to a normal individual with a value set
at 100%. Similarly, HOMA of insulin sensitivity (HOMA %S) values represent a
measure of insulin sensitivity relative to a normal individual, again with a
value of 100%. The HOMA of insulin resistance is a reciprocal measure of the
%S values.
Urinary corticosteroid metabolites. Urinary corticosteroid metabolite
analysis was performed by gas chromatography/mass spectrometry (GC/MS)
as described previously (20). The sum of total cortisol metabolites (tetrahy-
drocortisol [THF ], tetrahydrocortisone [THE], 5-THF, -cortolone, cortisone
[E], cortisol [F], -cortolone, -cortol, and -cortol) provides a reflection of
cortisol secretion rate. The ratio of tetrahydrometabolites of cortisol (THF 

5THF) to those of cortisone (THE) provides a reflection of 11-HSD1 activity
when considered with the ratio of urinary free cortisol to cortisone, which
more accurately reflects renal 11-HSD2 activity (20). The ratios of cortols to
cortolones and of 11-hydroxy-etiocholanolone and 11-hydroxy-andros-
terone combined to 11oxo-etiocholanolone also reflect 11-HSD1 activity
(24). The activities of 5- and 5-reductases can be inferred from measuring
the ratio of 5 THF to THF and androsterone to etiocholanolone.
RNA extraction and reverse transcription. Following subcutaneous adi-
pose tissue biopsy, total RNA was extracted using a single-step extraction
method (Magmax 96; Applied Biosystems, Foster City, CA) as per the
manufacturer’s guidelines. RNA integrity and quantity were assessed using a
Nanodrop spectrophotometer (Wilmington, DE).
One microgram of total RNA was initially denatured by heating to 70°C for
5 min. Thirty units of avian myeloblastososis virus, 200 ng of random primers,
20 units of ribonuclease inhibitor, and 40 nmol of deoxy–nucleoside triphos-
phates with 5 reaction buffer were added to the RNA, and the reverse
transcriptase reaction was carried out at 37°C for 1 h. The reaction was
terminated by heating the cDNA to 95°C for 5 min.
Real-time PCR. mRNA levels of genes of interest were determined using an
ABI 7500 sequence detection system (Perkin-Elmer and Applied Biosystems,
Warrington, U.K.). Reactions were performed in 25-l volumes on 96-well
plates in reaction buffer containing 2 TaqMan Universal PCR Master mix
(Applied Biosystems, Foster City, CA). Probes and primers for all genes were
supplied by assay on demand (Applied Biosystems). All reactions were
normalized against the housekeeping gene 18S rRNA, provided as a preopti-
mized control probe.
Data were measured as the cycle number at which logarithmic PCR plots
cross a calculated threshold line (CT) and used to determine CT values
[(CT of the target gene) 	 (CT of the housekeeping gene). Data were
expressed as arbitrary units (AU) using the following transformation: expres-
sion  105  (2	CT) AU.
Statistical analysis. Data are presented as means  SE unless otherwise
stated. Area under the curve (AUC) analysis was performed using the
trapezoidal method. For comparison of single variables, t tests have been used
(or nonparametric equivalents where data were not normally distributed).
Regression analyses were performed using Pearson correlations; where more
than one variable was considered, multiple linear regression analysis was
used. All analysis was performed using SigmaStat 3.1 (Systat Software, Point
Richmond, CA).
RESULTS
A total of 101 (66 women and 35 men) volunteers were
recruited into the study; 48 women (72.7%) and 17 men
(48.6%) had normal fasting glucose levels and normal
glucose tolerance. Two women (3.0%) and three men
TABLE 2
Urinary corticosteroid metabolite analysis performed by GC/MS on 24-h urine samples from 73 obese volunteers divided by sex and
glucose tolerance
Women Men
Normal IGT P Normal IGT P
n 35 11 14 12
Corticosteroid metabolite production (g/24h)
Total glucocorticoid metabolites 7,453 2,693 9,964 4,741 0.03 13,743 3,229* 16,871 7,619† 0.17
Total cortisol metabolites (Fm) 3,088 1,230 3,933 2,103 0.10 5,481 1,484* 6,679 2,911† 0.19
Total cortisone metabolites (Em) 4,364 1,697 6,031 2,702 0.02 8,263 1,971* 10,192 4,833† 0.18
THF 1,440 958 1,756 910 0.32 2,387 481‡ 2,757 1,346† 0.34
5THF 1,087 597 1,382 929 0.21 1,997 1,176‡ 2,553 1,395† 0.27
THE 2,777 1,670 3,677 1,720 0.12 5,183 1,562* 6,274 3,421† 0.29
UFF 56  76 48  22 0.74 80 29 98  40‡ 0.20
UFE 79 37 83  35 0.72 127 43* 152 71‡ 0.27
-cortol 303 155 351 179 0.37 415 112† 535 185† 0.05
-Cortol 379 183 395 157 0.79 603 232‡ 737 366‡ 0.26
-Cortolone 1,243 516 1,612 729 0.06 1,908 534* 2,499 830‡ 0.04
-Cortolone 524 278 659 328 0.17 1,046 280* 1,267 697† 0.28
Androsterone 1,054 746 1,371 1,009 0.25 2,246 900* 2,602 2,169 0.58
Etiocholanolone 1,020 742 1,192 737 0.49 2,075 1,081* 2,296 1,999 0.72
Corticosteroid metabolite ratios
UFF-to-UFE 0.64 0.53 0.63 0.25 0.93 0.63 0.11 0.66 0.13 0.48
(THF 
 5THF)-to-THF 0.98 0.39 0.84 0.18 0.24 0.86 0.0.16 0.87 0.19 0.88
Cortols-to-cortolones 0.39 0.1 0.33 0.05 0.06 0.35 0.07 0.34 0.09 0.94
(11OH-and 
 11OH-etio)–to–11oxo-etio 3.17 2.0 3.38 1.87 0.76 3.23 1.18 2.83 1.29 0.41
Fm-to-Em 0.73 0.23 0.64 0.12 0.21 0.67 0.12 0.66 0.12 0.92
Androsterone-to-etiocholanolone 1.15 0.55 1.14 0.43 0.99 1.27 0.58 1.24 0.47 0.89
5THF-to-THF 0.84 0.41 0.76 0.26 0.53 0.84 0.45 0.97 0.41 0.47
Data are means  SD. UFF, urinary free cortisol; UFE, urinary free cortisone; 11OH-and, 11hydroxyandrosterone; 11OH-etio, 11hydroxye-
tiocholanolone; 11oxo-etio, 11oxo-etiocholanolone; Fm, cortisol 
 THF 
 5THF 
 -cortol 
 -cortol; Em, cortisone 
 THE 

-cortolone 
 -cortolone. *P  0.0001; †P  0.05; ‡P  0.01 vs. women.
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(8.6%) had impaired fasting glucose (IFG) (5.6 mmol/l),
and within this group, two men and no women had IGT.
IGT with normal fasting glucose concentrations was ob-
served in 15 women (22.7%) and 10 men (28.6%). Type 2
diabetes was diagnosed in two women (3.0%) and five men
(14.3%), and all subjects with type 2 diabetes had IFG.
Taking into account the sexual dimorphism described in
body composition and glucocorticoid metabolite produc-
tion rates, subsequent analysis was performed separately
in men and women.
Normal glucose tolerance versus IGT and IFG. IGT
was associated with increased waist circumference (103
1.3 vs. 111 2 cm, P 0.002) and waist-to-hip ratio (WHR)
(0.87  0.01 vs. 0.90  0.01, P  0.05) in women but not in
men (waist circumference 114  3 vs. 116  3 cm, P 
0.57; WHR 0.98  0.02 vs. 0.99  0.01, P  0.46).
A1C was increased in both men and women with IGT,
although this only reached statistical significance in men
(men 5.3  0.1 vs. 5.9  0.3%, P  0.05; women 5.4  0.1
vs. 5.7  0.1%, P  0.08). Surprisingly, measures of insulin
resistance (HOMA-R, fasting and 2-h insulin concentra-
tions) were not different between groups (Table 1). Fur-
thermore, body composition analysis by DEXA failed to
show differences in fat-free mass or total or regional fat
mass between those patients with normal glucose toler-
ance or IGT (Table 1). Although men and women were not
different in terms of insulin resistance (as measured by
HOMA, fasting insulin, 2-h insulin or insulin AUC across
the 75-g OGTT, percent trunk fat and absolute total and
trunk fat mass were higher in women with correspond-
ingly lower fat-free masses (Table 1).
Urinary steroid metabolite analysis by GC/MS demon-
strated clear sexual dimorphism with increased total and
individual glucocorticoid metabolite production rates in
men compared with women for subjects with and without
IGT (Table 2). When analyzed according to glucose toler-
ance, total glucocorticoid production rates were higher in
women with IGT compared with women with normal
glucose tolerance (10,133  1,488 vs. 7,453  469, respec-
tively, P  0.05), but this relationship was not observed in
men (16,871  2,113 vs. 13,743  863, respectively, P 
0.17). Furthermore, there were no differences in absolute
production rates for individual metabolites or activities of
metabolizing enzymes (in particular 11-HSD1 or 5R)
when comparing normal and IGT subjects (Table 2).
Adipose tissue biopsy gene expression. Successful
isolation of total RNA and generation of cDNA from
subcutaneous adipose tissue biopsies was achieved in 90
volunteers. All samples expressed 11-HSD1, H6PDH, GR,
and 5R1. In contrast, 5R2 was only expressed in 5 of 90
samples and only at very low levels (data not shown).
Whereas 11-HSD1, GR, and 5R1 mRNA expression
levels were similar in men and women, H6PDH expression
was higher in biopsies from male volunteers (2.3  0.4 vs.
1.6  0.5 AU, P  0.05).
In women only, adipose tissue 11-HSD1 expression
was higher in those with IGT than in those with normal
glucose tolerance (0.5  0.06 vs. 0.29  0.03 AU, P 
0.005), despite fat mass (total and regional) being similar
between the two groups (Fig. 1A). Moreover, expression
correlated with glucose AUC across the OGTT (R  0.44,
P  0.005) (Fig. 1B) but not with fat mass (total fat mass
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FIG. 1. In women only, IGT is associated with increased adipose tissue 11-HSD1 but decreased H6PDH mRNA expression (A) without alteration
in fat mass; 11-HSD1 mRNA levels correlate with glucose AUC across an OGTT (B). However, in men with IGT, adipose 11-HSD1, H6PDH, GR,
and 5R1 mRNA expression is not dysregulated (C and D). , normal glucose tolerance; f, IGT.
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R  0.12, P  NS; trunk fat mass R  0.15, P  NS).
H6PDH expression was lower in female volunteers with
IGT (0.79  0.1 vs. 1.38  0.14 AU, P  0.05), but GR and
5R1 expression did not differ (Fig. 1A). In contrast to our
findings in women, expression of 11-HSD1, H6PDH, GR,
and 5R1 in adipose tissue biopsies from men did not
differ between those with and those without IGT and did
not relate to glucose levels across an OGTT (Fig. 1C
and D).
Regression analyses. Univariate regression analysis re-
vealed positive relationships between 5R activity (as
measured by both the urinary androsterone–to–etiochol-
anolone and 5THF-to-THF ratios) and markers of insulin
resistance. In women, significant correlations were ob-
served with fasting insulin, 2-h insulin levels after 75 g oral
glucose, AUC insulin across the OGTT, and HOMA-R
(Table 3 and Fig. 2A–D). In men, a similar pattern was
observed (Table 3; Fig. 2A–D), but in addition, increased
5R activity was associated with decreased pancreatic
-cell function as calculated from the HOMA-%B (Table 3).
Activity of 5R increased with increasing total and
regional fat and fat-free mass in men but not in women
(Table 3). While these relationships remained significant,
they were weaker than those observed with markers of
insulin resistance. There was no relationship in either sex
with fat distribution as measured by waist circumference,
WHR, or the trunk fat–to–limb fat ratio via DEXA.
Total glucocorticoid secretion rate increased with total
and regional fat and fat-free mass in women but not in men
and was weakly associated with 2-h insulin concentration
after 75 g oral glucose (Table 4). Global 11-HSD1 activity
as measured by the 5 THF
 THF–to–THE ratio was
unrelated to metabolic or anthropometric variables in
women and only weakly related to HOMA-R in men (R 
0.38, P  0.04). 11-HSD2 inactivates cortisol to cortisone
in mineralocorticoid target tissues, notably the kidney.
Activity is reflected in the ratio of urinary free cortisol to
cortisone. This was unrelated to metabolic parameters
with the exception of 2-h insulin levels in men only (R 
0.389, P  0.03) and inversely related to WHR in women
only (R  	0.30, P  0.04).
Using multivariate modeling to correct for total and
regional fat mass, 5R activity remained an independent
predictor of insulin secretion across the OGTT (2-h insulin
P  0.005; insulin AUC P  0.005) in women. In men, 5R
activity and not fat mass independently predicted fasting
insulin levels (P  0.05), HOMA-%B (P  0.05), HOMA-%S
(P  0.05), and HOMA-R (P  0.05).
DISCUSSION
In this unselected cohort of obese patients, we have
identified the prevalence of IGT to be 22.7% in women and
34.2% in men and the prevalence of type 2 diabetes to be
3.0% in women and 14.3% in men. This was associated with
central fat distribution (but not absolute fat mass) in
women and unrelated to fat mass or distribution in men.
In this cohort, subcutaneous adipose tissue 11-HSD1
mRNA expression was higher in women with IGT and
correlated with glucose secretion across the OGTT but
was unrelated to fat mass, consistent with our previous
observations (25). Previous studies have examined 11-
HSD1 mRNA expression and activity in adipose tissue in
the context of fat mass with variable results. Within the
subcutaneous depot, most studies, although not all, have
suggested increased expression with indexes of obesity
(25–29), but relative expression within the intra-abdominal
depot remains controversial. Importantly, the expression
of 11-HSD1 in adipose tissue and its relationship with
TABLE 3
Correlation of metabolic parameters with 5-reductase activity as assessed by the urinary 5THF-to-THF and androsterone-to-
etiocholanolone ratios analyzed by GC/MS
Women (n  49) Men (n  30)
Androsterone-to-
etiocholanolone ratio 5THF-to-THF ratio
Androsterone-to-
etiocholanolone ratio 5THF-to-THF ratio
Correlation
coefficient (R) P
Correlation
coefficient (R) P
Correlation
coefficient (R) P
Correlation
coefficient (R) P
Insulin sensitivity and glucose
tolerance
Fasting glucose 0.082 0.58 0.065 0.66 0.26 0.17 0.22 0.26
2-h glucose 0.14 0.35 0.13 0.37 0.13 0.51 0.81 0.67
Fasting insulin 0.33 0.022 0.27 0.07 0.53 0.003 0.50 0.006
2-h insulin 0.51 0.0002 0.51 0.0002 0.14 0.48 0.35 0.06
AUC insulin 0.38 0.007 0.40 0.004 0.31 0.10 0.46 0.01
A1C 	0.11 0.47 	0.09 0.58 0.39 0.04 0.14 0.47
HOMA-%B 0.26 0.07 0.22 0.13 0.47 0.01 0.55 0.003
HOMA-%S 	0.27 0.06 	0.23 0.11 	0.43 0.02 	0.53 0.003
HOMA-R 0.33 0.02 0.26 0.07 0.52 0.004 0.49 0.008
Anthropometry
BMI 0.14 0.35 	0.02 0.87 0.28 0.13 0.32 0.08
Waist circumference 0.15 0.33 0.02 0.90 0.03 0.89 0.14 0.46
WHR 0.09 0.56 0.16 0.27 0.09 0.62 0.05 0.81
Body composition (DEXA)
Trunk fat mass 0.06 0.67 	0.04 0.78 0.44 0.02 0.46 0.01
Trunk fat-free mass 0.11 0.45 	0.006 0.97 0.41 0.03 0.41 0.03
Total fat mass 0.02 0.90 	0.10 0.51 0.36 0.06 0.38 0.04
Total fat-free mass 0.09 0.56 	0.02 0.87 0.493 0.008 0.43 0.02
Total % fat 	0.02 0.89 	0.07 0.62 0.18 0.37 0.24 0.23
Trunk fat–to–limb fat ratio 0.10 0.51 0.10 0.52 0.27 0.17 0.26 0.18
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insulin resistance and glucose tolerance has not been
examined before. While expression studies were only
performed in subcutaneous adipose tissue, enhanced cor-
tisol generation through increased 11-HSD1 mRNA ex-
pression may contribute to glucose intolerance through
increased lipolysis (30,31) and generation of free fatty
acids, which impair peripheral glucose uptake (32). How-
ever, due to the small volumes of tissue obtained, activity
studies were not performed and it is possible that de-
creased H6PDH expression that we also observed in the
IGT group may decrease 11-HSD1 oxo-reductase activity
by limiting cofactor supply.
Sexually dimorphic activity and expression of 11-HSD1
has been described in some studies (33) but not all (34). In
our cohort, urinary GC/MS analysis was similar in men and
women. Studies examining sex-specific regulation of ex-
pression within adipose tissue are lacking. In nonadipose
tissue, estradiol has been shown to regulate expression
levels, and it is possible that this may contribute to our
observations; however, the published data are often con-
tradictory with studies showing both increased and de-
creased expression (35–38). With the exception of
dehydroepiandrosterone (39), there is little evidence to
support a role for regulation by androgens (35,38). Sexu-
ally dimorphic expression of H6PDH has not been de-
scribed previously, and the observed increase in
expression in men will need to be endorsed with dedicated
activity studies to see if changes in H6PDH expression
translate into alterations in glucocorticoid availability.
However, it is possible that this could contribute to
differences in fat distribution between men and women,
with the consequent increase in cardiovascular risk (40).
In our study, in both sexes, 5R activity as measured by
urinary glucocorticoid metabolite ratios increased with
indexes of insulin resistance, an observation that was
independent of fat mass. The role of 5R in the control of
body composition and insulin sensitivity has not been
explored in detail in the published literature. The global
measures of activity that we have used in this study do not
allow us to distinguish between 5R1 and 5R2, and
whereas patients with 5R2 mutations have clear evidence
of abnormal hepatic cortisol metabolism (41), the contri-
bution of 5R1 is yet to be clarified. Sexual dimorphism of
5R activity has been described with increased activity in
male subjects (10,34). In our study, absolute levels of 5-
and 5-reduced metabolites were higher in men (as was
total glucocorticoid production rate), but the relative
balance of 5R and 5R activity was not different. Fur-
thermore, 5R1 mRNA expression in subcutaneous adi-
pose tissue was similar in men and women. Studies in
small cohorts of patients have shown enhanced 5R
activity with obesity (42) and type 2 diabetes (43) and
regulation of 5R and 5R activity by dietary macro-
nutrient composition; high-fat, low-carbohydrate and
moderate-fat, moderate-carbohydrate diets decrease
5R and 5R activity in the context of weight loss (44).
Thiazolidinedione treatment of obese Zu¨cker rats de-
creases 5R1 expression in the liver (45), but similar
experiments in humans have not been performed. How-
ever, we have recently shown that following weight loss
with consequent insulin sensitization, 5R activity de-
creased (46). 5R has been implicated in the pathogen-
esis of the insulin resistance associated with PCOS, in
that patients with PCOS are more insulin resistant
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compared with body composition–matched control sub-
jects (4) and have increased 5R activity (47). More-
over, within a cohort of patients with PCOS, 5R
activity correlates with insulin resistance (48). Our
findings are consistent with these data and extend this
observation to healthy obese women and men, as well as
demonstrate that the relationship (in both sexes) is
independent of fat mass. In the context of insulin
resistance, we postulate that increased 5R activity
represents a compensatory mechanism to decrease lo-
cal glucocorticoid availability and occurs in conjunction
with the decrease in 11-HSD1 activity (as evidenced by
reduced cortisol generation following oral cortisone
administration and decreased urinary 5- 
 THF–to–
THE ratios) that we and others have previously de-
scribed in obesity (22,26). These processes act together
(decreased generation of cortisol through a reduction in
11-HSD1 and increased inactivation of cortisol through
enhanced 5R activity) to decrease local glucocorticoid
availability and decrease GR activation specifically
within the liver, with the aim of maintenance of hepatic
insulin sensitivity. A further impact of these changes
will be to drive the hypothalamo-pituitary-adrenal axis
in order to maintain circulating cortisol levels. While we
believe that the changes that we have observed largely
reflect hepatic glucocorticoid metabolism, a direct ef-
fect upon insulin secretion cannot be excluded. How-
ever, this remains highly speculative, bearing in mind
that evidence of A-ring reductase expression in human
pancreatic islets is lacking.
Pharmacological manipulation of glucocorticoid avail-
ability through prereceptor metabolism adds credence to
our observations. Selective 11-HSD1 inhibitors that de-
crease local glucocorticoid availability remain an exciting
therapeutic prospect. Significant improvements in insulin
sensitivity, glucose tolerance, and lipid profiles following
short-term administration in rodents and primates have
been observed. Human clinical studies are still eagerly
awaited. Conversely, Finasteride (5R2 inhibitor) and
Dutasteride (combined 5R1 and 5R2 inhibitor) are
widely used in the treatment of prostatic hypertrophy (49)
based upon their action upon androgen metabolism. How-
ever, by decreasing glucocorticoid inactivation, they may
have a detrimental impact upon insulin sensitivity, but the
studies to address this question have not been performed.
In conclusion, this study adds to the growing body of
evidence that supports a role for 5R in the control of
insulin sensitivity in simple obesity. While little is cur-
rently known about the regulation of 5R activity, limiting
local glucocorticoid availability through enhanced 5R
and/or inhibition of 11-HSD1 activity may have significant
clinical benefits. Finally, prospective studies examining
the changes in activity and expression of these enzymes
over time may begin to shed light on their potential role in
the development of IGT and type 2 diabetes.
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